New contender in diabetes and obesity.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
  • Additional Information
    • Subject Terms:
    • Abstract:
      The article reports on the announcement of Pfizer in its intention of development of a potential new treatment for obesity, Type 2 diabetes and related disorders. Obesity and diabetes are fast becoming a near-epidemic levels and the need for new treatment options is in demand. The drug is undergoing a Phase I clinical development in Europe known as DGAT - 1 or diacylglycerol acyltransferase 1.